# Clinical, social, molecular, and genetic predictors of cognitive resilience in long-living adults without dementia

**Authors:** Ekaterina Spektor, Aleksandra Mamchur, Mariia Bruttan, Liliya Artemieva, Antonina Rumyantseva, Lorena Matkava, Mikhail Ivanov, Veronika Daniel, Sergey Igorevich Mitrofanov, Irina Strazhesko, Vladimir Yudin, Valentin Makarov, Anton Keskinov, Olga Tkacheva, Daria Kashtanova, Sergey Yudin, Veronika Skvortsova

PMC · DOI: 10.3389/frdem.2025.1699695 · Frontiers in Dementia · 2026-02-16

## TL;DR

This study explores factors that help some elderly people maintain cognitive function despite aging, including genetic and health-related influences.

## Contribution

The study identifies a novel genetic variant in SYNGAP1 and highlights complex regulatory mechanisms underlying cognitive resilience.

## Key findings

- Limited mobility, depression, and anemia were key accelerators of cognitive decline.
- A missense mutation in SYNGAP1 (Ile1115Thr) was linked to cognitive resilience.
- APOE ε4 showed no significant association with cognitive resilience in this population.

## Abstract

Long-living adults often maintain cognitive function despite neuropathological changes, which is often attributed to cognitive resilience (CR)—a combined effect of cognitive and cerebral reserves. CR is influenced by genetic, clinical, sociodemographic, and environmental factors.

We investigated genetic, clinical, and environmental predictors of CR in 198 dementia-free long-living adults via two neuropsychological examinations over a 2-year period, a geriatric assessment, and a genome-wide association study (GWAS).

Limited mobility, reduced walking, hearing impairment, depression, anemia, lower quality of life, and decreased BMI were key accelerators of CI. Depression, hypercholesterolemia, and lack of hobbies increased the risk of mild cognitive impairment (MCI)-to-dementia progression. GWAS identified CR-associated genetic variants, including a missense mutation in SYNGAP1 (Ile1115Thr) not previously linked to cognitive disorders.

Our findings corroborated established risk factors for cardiovascular diseases and identified population-specific patterns, with APOE ε4 showing no significant association. Both protein-coding regions and non-coding elements were implicated in CI, suggesting that it is underlain by complex regulatory mechanisms.

## Linked entities

- **Genes:** SYNGAP1 (synaptic Ras GTPase activating protein 1) [NCBI Gene 8831], APOE (apolipoprotein E) [NCBI Gene 348]
- **Diseases:** dementia (MONDO:0001627), anemia (MONDO:0002280)

## Full-text entities

- **Genes:** SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, LOC105370228 (uncharacterized LOC105370228) [NCBI Gene 105370228], GGNBP1 (gametogenetin binding protein 1 (pseudogene)) [NCBI Gene 449520], APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, NFASC (neurofascin) [NCBI Gene 23114] {aka NEDCPMD, NF, NRCAML}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, SYNGAP1 (synaptic Ras GTPase activating protein 1) [NCBI Gene 8831] {aka MRD5, RASA5, SYNGAP}, LINC03209 (long intergenic non-protein coding RNA 3209) [NCBI Gene 102723446], LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, PRKXP1 (PRKX pseudogene 1) [NCBI Gene 441733], ERC1 (ELKS/RAB6-interacting/CAST family member 1) [NCBI Gene 23085] {aka Cast2, ELKS, ERC-1, RAB6IP2}, TDRD3 (tudor domain containing 3) [NCBI Gene 81550], NR2F2-AS1 (NR2F2 antisense RNA 1) [NCBI Gene 644192], GGTLC5P (gamma-glutamyltransferase light chain 5 pseudogene) [NCBI Gene 653590] {aka GGT}, SV2B (synaptic vesicle glycoprotein 2B) [NCBI Gene 9899] {aka HsT19680, SLC22B2}, LINC01344 (long intergenic non-protein coding RNA 1344) [NCBI Gene 400799] {aka GS1-122H1.2}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, KRT16 (keratin 16) [NCBI Gene 3868] {aka CK16, FNEPPK, K16, K1CP, KRT16A, NEPPK}, MUL1 (mitochondrial E3 ubiquitin protein ligase 1) [NCBI Gene 79594] {aka C1orf166, GIDE, MAPL, MULAN, RNF218}, LRPAP1 (LDL receptor related protein associated protein 1) [NCBI Gene 4043] {aka A2MRAP, A2RAP, HBP44, MYP23, RAP, alpha-2-MRAP}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, LOC107986537 (uncharacterized LOC107986537) [NCBI Gene 107986537], SV2A (synaptic vesicle glycoprotein 2A) [NCBI Gene 9900] {aka DEE113, SLC22B1, SV2}, RAP1A (RAP1A, member of RAS oncogene family) [NCBI Gene 5906] {aka C21KG, G-22K, KREV-1, KREV1, RAP1, SMGP21}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, RAP1GAP2 (RAP1 GTPase activating protein 2) [NCBI Gene 23108] {aka GARNL4, RAP1GA3}, RPTOR (regulatory associated protein of MTOR complex 1) [NCBI Gene 57521] {aka KOG1, Mip1}, DIAPH3 (diaphanous related formin 3) [NCBI Gene 81624] {aka AN, AUNA1, DIA2, DRF3, NSDAN, diap3}, NDUFB3 (NADH:ubiquinone oxidoreductase subunit B3) [NCBI Gene 4709] {aka B12, CI-B12, MC1DN25}
- **Diseases:** hypertension (MESH:D006973), brain damage (MESH:D001925), anemia (MESH:D000740), carotid atherosclerosis (MESH:D002340), tauopathy (MESH:D024801), cardiovascular diseases (MESH:D002318), amyloid (MESH:C000718787), Dementia (MESH:D003704), chronic pain (MESH:D059350), Depression (MESH:D003866), heart failure (MESH:D006333), hypercholesterolemia (MESH:D006937), amyloid plaques (MESH:D058225), CR (MESH:D003072), reduced walking (MESH:D013009), urinary incontinence (MESH:D014549), neurodevelopmental disorders (MESH:D002658), dyslipidemia (MESH:D050171), Parkinson's disease (MESH:D010300), neurodegeneration (MESH:D019636), somatic disorders (MESH:D013001), Metabolic syndrome (MESH:D024821), platelet aggregation (MESH:D001791), traumatic brain injury (MESH:D000070642), atrophy (MESH:D001284), Lewy body (MESH:D020961), MCI (MESH:D060825), AD (MESH:D000544), cancer (MESH:D009369), diabetes (MESH:D003920), impaired memory and learning (MESH:D007859), ACA (MESH:D020521), auditory neuropathy (MESH:C538268), obese (MESH:D009765), neurofibrillary tangles (MESH:D055956), hypoxia (MESH:D000860), Limited mobility (MESH:D051346), hearing impairment (MESH:D034381)
- **Chemicals:** caffeine (MESH:D002110), vitamin A, C, and E (-), amino acid (MESH:D000596), urea (MESH:D014508), lipid (MESH:D008055), glucose (MESH:D005947), creatinine (MESH:D003404), calcium (MESH:D002118), threonine (MESH:D013912), alcohol (MESH:D000438), vitamin D (MESH:D014807), bilirubin (MESH:D001663), Isoleucine (MESH:D007532), vitamin A (MESH:D014801), cholesterol (MESH:D002784)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs191549504, rs7221569, rs150254300, rs79231290, rs1161008264, rs181605481, rs146134558, rs114530160, rs149259839, rs116878859, rs115709053, rs139146816, isoleucine-to-threonine replacement at position 1, rs191770718, threonine at position 1,115, rs551037526, rs192721259, rs200843758, c.-173C>T, rs150184078, rs137961036

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950572/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950572/full.md

## References

53 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950572/full.md

---
Source: https://tomesphere.com/paper/PMC12950572